{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:47:19Z","timestamp":1773895639879,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"ational Natural Science Foundation of China","award":["82401638"],"award-info":[{"award-number":["82401638"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271434"],"award-info":[{"award-number":["82271434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171396"],"award-info":[{"award-number":["82171396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"DOI":"10.1007\/s11481-025-10276-5","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:43:32Z","timestamp":1769845412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose IL-2 Ameliorates Experimental Autoimmune Myasthenia Gravis in Rats by Restoring the CD4-positive Helper T-cell Balance Via the JAK\/STAT5 Pathway"],"prefix":"10.1007","volume":"21","author":[{"given":"Shanshan","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanfan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanlu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"1","key":"10276_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2021-220955","volume":"81","author":"IR Adriawan","year":"2022","unstructured":"Adriawan IR, Atschekzei F, Dittrich-Breiholz O, Garantziotis P, Hirsch S, Risser LM, Kosanke M, Schmidt RE, Witte T, Sogkas G (2022) Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis. Ann Rheum Dis 81(1):124\u2013131. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220955","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10276_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neurol.2024.09.006","volume":"180","author":"S Attarian","year":"2024","unstructured":"Attarian S (2024) New treatment strategies in myasthenia gravis. Rev Neurol (Paris) 180(9):971\u2013981. https:\/\/doi.org\/10.1016\/j.neurol.2024.09.006","journal-title":"Rev Neurol (Paris)"},{"issue":"18","key":"10276_CR3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","volume":"20","author":"C Barnett","year":"2019","unstructured":"Barnett C, Tabasinejad R, Bril V (2019) Current pharmacotherapeutic options for myasthenia gravis. Expert Opin Pharmacother 20(18):2295\u20132303. https:\/\/doi.org\/10.1080\/14656566.2019.1682548","journal-title":"Expert Opin Pharmacother"},{"key":"10276_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","volume":"56","author":"CJ Bell","year":"2015","unstructured":"Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB (2015) Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun 56:66\u201380. https:\/\/doi.org\/10.1016\/j.jaut.2014.10.002","journal-title":"J Autoimmun"},{"issue":"97","key":"10276_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf2047","volume":"9","author":"D Casta\u00f1o","year":"2024","unstructured":"Casta\u00f1o D, Wang S, Atencio-Garcia S, Shields EJ, Rico MC, Sharpe H, Bustamante J, Feng A, Le Coz C, Romberg N, Tobias JW, Utz PJ, Henrickson SE, Casanova JL, Bonasio R, Locci M (2024) IL-12 drives the differentiation of human T follicular regulatory cells. Sci Immunol 9(97):eadf2047. https:\/\/doi.org\/10.1126\/sciimmunol.adf2047","journal-title":"Sci Immunol"},{"issue":"5","key":"10276_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","volume":"25","author":"P Cavalcante","year":"2012","unstructured":"Cavalcante P, Bernasconi P, Mantegazza R (2012) Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 25(5):621\u2013629. https:\/\/doi.org\/10.1097\/WCO.0b013e328357a829","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"10276_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451268","volume":"54","author":"M \u00c7ebi","year":"2024","unstructured":"\u00c7ebi M, \u00c7akar A, Durmu\u015f H, Akan O, Aysal F, Parman Y, Saruhan-Direskeneli G (2024) In vitro modulation of T cells in myasthenia gravis by low-dose IL-2. Eur J Immunol 54(11):e2451268. https:\/\/doi.org\/10.1002\/eji.202451268","journal-title":"Eur J Immunol"},{"key":"10276_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578129","volume":"381","author":"M Cebi","year":"2023","unstructured":"Cebi M, Cakar A, Erdogdu E, Durmus-Tekce H, Yegen G, Ozkan B, Parman Y, Saruhan-Direskeneli G (2023) Thymoma patients with or without myasthenia gravis have increased Th17 cells, IL-17 production and ICOS expression. J Neuroimmunol 381:578129. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578129","journal-title":"J Neuroimmunol"},{"key":"10276_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803101","volume":"12","author":"P Chen","year":"2021","unstructured":"Chen P, Tang X (2021) Gut microbiota as regulators of Th17\/Treg balance in patients with myasthenia gravis. Front Immunol 12:803101. https:\/\/doi.org\/10.3389\/fimmu.2021.803101","journal-title":"Front Immunol"},{"key":"10276_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.molimm.2021.02.011","volume":"133","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhang XS, Wang YG, Lu C, Li J, Zhang P (2021) Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis. Mol Immunol 133:67\u201376. https:\/\/doi.org\/10.1016\/j.molimm.2021.02.011","journal-title":"Mol Immunol"},{"issue":"11","key":"10276_CR11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN (2024) Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol 24(11):830\u2013845. https:\/\/doi.org\/10.1038\/s41577-024-01035-3","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10276_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2021.03.020","volume":"54","author":"S Dikiy","year":"2021","unstructured":"Dikiy S, Li J, Bai L, Jiang M, Janke L, Zong X, Hao X, Hoyos B, Wang ZM, Xu B, Fan Y, Rudensky AY, Feng Y (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity 54(5):931\u2013946.e911. https:\/\/doi.org\/10.1016\/j.immuni.2021.03.020","journal-title":"Immunity"},{"issue":"5","key":"10276_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16233","volume":"31","author":"I Engebretsen","year":"2024","unstructured":"Engebretsen I, Gilhus NE, Kristiansen IS, S\u00e6ther EM, Lindberg-Schager I, Arneberg F, Bugge C (2024) The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data. Eur J Neurol 31(5):e16233. https:\/\/doi.org\/10.1111\/ene.16233","journal-title":"Eur J Neurol"},{"issue":"1","key":"10276_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119863","volume":"1872","author":"A Franke","year":"2025","unstructured":"Franke A, Dahl S, Funck M, Bakker H, Garbers C, Lokau J (2025) Interleukin-2 receptor \u03b1 (IL-2R\u03b1\/CD25) shedding is differentially regulated by N- and O-glycosylation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1872(1):119863. https:\/\/doi.org\/10.1016\/j.bbamcr.2024.119863","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"1","key":"10276_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"10276_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648408","volume":"12","author":"H Gra\u00dfhoff","year":"2021","unstructured":"Gra\u00dfhoff H, Comd\u00fchr S, Monne LR, M\u00fcller A, Lamprecht P, Riemekasten G, Humrich JY (2021) Low-Dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol 12:648408. https:\/\/doi.org\/10.3389\/fimmu.2021.648408","journal-title":"Front Immunol"},{"issue":"6","key":"10276_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/s1474-4422(24)00140-6","volume":"23","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Schett G, Mougiakakos D (2024) B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol 23(6):615\u2013624. https:\/\/doi.org\/10.1016\/s1474-4422(24)00140-6","journal-title":"Lancet Neurol"},{"key":"10276_CR18","doi-asserted-by":"publisher","unstructured":"He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, Feng R, Huang B, Luan H, Jia Y, Jin Y, Zhang X, Shao M, Wang Y, Zhang X, Li J, Zhao X, Wang H, Liu T, Xiao Xian, Su Yin, Mu Rong, Ye Hua, Li Ru, Liu Xu, Liu Yanying, Li Chun, Liu Huixin, Hu Fanlei, Guo Jianping, Liu Wanli, Zhang Wen-Bin, Jacob Alexander, Ambrus Julian L. Jr, Ding Changhai, Yu Di, Sun Xiaolin, Li Zhanguo (2022) Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial. JAMA Netw Open 5(11):e2241451. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41451","DOI":"10.1001\/jamanetworkopen.2022.41451"},{"issue":"10","key":"10276_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez R, P\u00f5der J, LaPorte KM, Malek TR (2022) Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol 22(10):614\u2013628. https:\/\/doi.org\/10.1038\/s41577-022-00680-w","journal-title":"Nat Rev Immunol"},{"key":"10276_CR20","doi-asserted-by":"publisher","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"10276_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107434","volume":"93","author":"H Huang","year":"2021","unstructured":"Huang H, Ran H, Liu X, Yu L, Qiu L, Lin Z, Ou C, Lu Y, Yang W, Liu W (2021) Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses. Int Immunopharmacol 93:107434. https:\/\/doi.org\/10.1016\/j.intimp.2021.107434","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10276_CR22","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, Leroux D, Vazquez T, Riemekasten G, Smolen JS, Tsokos G, Klatzmann D (2022) Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis 81(12):1685\u20131694. https:\/\/doi.org\/10.1136\/ard-2022-222501","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10276_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","volume":"141","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger F, Krishnarajah S, Kramer M, Utz SG, Galli E, Lutz M, Zwicky P, Akarca AU, Jurado NP, Ulutekin C, Bamert D, Widmer CC, Piccoli L, Sallusto F, N\u00fa\u00f1ez NG, Marafioti T, Schneiter D, Opitz I, Lanzavecchia A, Jung Hans H., De Feo Donatella, Mundt Sarah, Schreiner Bettina, Becher Burkhard (2021) Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol 141(6):901\u2013915. https:\/\/doi.org\/10.1007\/s00401-021-02299-y","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10276_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20(2):84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w","journal-title":"Nat Rev Neurol"},{"key":"10276_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040598","author":"V Janelle","year":"2021","unstructured":"Janelle V, Delisle JS (2021) T-cell dysfunction as a limitation of adoptive immunotherapy: current concepts and mitigation strategies. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13040598","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10276_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1084\/jem.20111174","volume":"209","author":"RJ Johnston","year":"2012","unstructured":"Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S (2012) STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med 209(2):243\u2013250. https:\/\/doi.org\/10.1084\/jem.20111174","journal-title":"J Exp Med"},{"issue":"49","key":"10276_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq6618","volume":"10","author":"A Kawajiri","year":"2024","unstructured":"Kawajiri A, Li J, Koinuma K, Yang Z, Yoon HJ, Yi J, Nagashima H, Ishii M, Gao F, Sato K, Tayama S, Harigae H, Iwakura Y, Ishii N, Sher A, Ishigaki K, Zhu J, Kim KS, Kawabe T (2024) Naturally arising memory-phenotype CD4(+) T lymphocytes contain an undifferentiated population that can generate T(H)1, T(H)17, and T(reg) cells. Sci Adv 10(49):eadq6618. https:\/\/doi.org\/10.1126\/sciadv.adq6618","journal-title":"Sci Adv"},{"issue":"5","key":"10276_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK (2015) The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 15(5):283\u2013294. https:\/\/doi.org\/10.1038\/nri3823","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10276_CR29","doi-asserted-by":"publisher","first-page":"18574","DOI":"10.3390\/ijms151018574","volume":"15","author":"A Kosmaczewska","year":"2014","unstructured":"Kosmaczewska A (2014) Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity. Int J Mol Sci 15(10):18574\u201318592. https:\/\/doi.org\/10.3390\/ijms151018574","journal-title":"Int J Mol Sci"},{"issue":"8022","key":"10276_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-024-07627-2","volume":"631","author":"C Law","year":"2024","unstructured":"Law C, Wacleche VS, Cao Y, Pillai A, Sowerby J, Hancock B, Horisberger A, Bracero S, Skidanova V, Li Z, Adejoorin I, Dillon E, Benque IJ, Nunez DP, Simmons DP, Keegan J, Chen L, Baker T, Brohawn PZ, Rao DA (2024) Interferon subverts an AHR-JUN axis to promote CXCL13(+) T cells in lupus. Nature 631(8022):857\u2013866. https:\/\/doi.org\/10.1038\/s41586-024-07627-2","journal-title":"Nature"},{"issue":"82","key":"10276_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade8162","volume":"8","author":"C Le Coz","year":"2023","unstructured":"Le Coz C, Oldridge DA, Herati RS, De Luna N, Garifallou J, Cruz Cabrera E, Belman JP, Pueschl D, Silva LV, Knox AVC, Reid W, Yoon S, Zur KB, Handler SD, Hakonarson H, Wherry EJ, Gonzalez M, Romberg N (2023) Human T follicular helper clones seed the germinal center-resident regulatory pool. Sci Immunol 8(82):eade8162. https:\/\/doi.org\/10.1126\/sciimmunol.ade8162","journal-title":"Sci Immunol"},{"issue":"10","key":"10276_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","volume":"22","author":"WJ Leonard","year":"2023","unstructured":"Leonard WJ, Lin JX (2023) Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov 22(10):827\u2013854. https:\/\/doi.org\/10.1038\/s41573-023-00746-x","journal-title":"Nat Rev Drug Discov"},{"key":"10276_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.expneurol.2018.11.006","volume":"312","author":"Y Li","year":"2019","unstructured":"Li Y, Guptill JT, Russo MA, Massey JM, Juel VC, Hobson-Webb LD, Howard JF, Chopra M, Liu W, Yi JS (2019) Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Exp Neurol 312:43\u201350. https:\/\/doi.org\/10.1016\/j.expneurol.2018.11.006","journal-title":"Exp Neurol"},{"issue":"6","key":"10276_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1293","volume":"10","author":"K Liang","year":"2021","unstructured":"Liang K, He J, Wei Y, Zeng Q, Gong D, Qin J, Ding H, Chen Z, Zhou P, Niu P, Chen Q, Ding C, Lu L, Chen XX, Li Z, Shen N, Yu D, Deng J (2021) Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr\/Tfh ratio in lupus. Clin Transl Immunology 10(6):e1293. https:\/\/doi.org\/10.1002\/cti2.1293","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10276_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2022.08.035","volume":"78","author":"TY Lim","year":"2023","unstructured":"Lim TY, Perpi\u00f1\u00e1n E, Londo\u00f1o MC, Miquel R, Ruiz P, Kurt AS, Kodela E, Cross AR, Berlin C, Hester J, Issa F, Douiri A, Volmer FH, Taubert R, Williams E, Demetris AJ, Lesniak A, Bensimon G, Lozano JJ, S\u00e1nchez-Fueyo A (2023) Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans. J Hepatol 78(1):153\u2013164. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.035","journal-title":"J Hepatol"},{"issue":"6","key":"10276_CR36","first-page":"2600","volume":"12","author":"YT Luo","year":"2020","unstructured":"Luo YT, Liang YF, He H, Zhang MT, Wang R, Li HL (2020) The immunosuppressant fingolimod ameliorates experimental autoimmune myasthenia gravis by regulating T-cell balance and cytokine secretion. Am J Transl Res 12(6):2600\u20132613","journal-title":"Am J Transl Res"},{"key":"10276_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060980","author":"A Mak","year":"2022","unstructured":"Mak A (2022) T cells, interleukin-2 and systemic lupus erythematosus-from pathophysiology to therapy. Cells. https:\/\/doi.org\/10.3390\/cells11060980","journal-title":"Cells"},{"issue":"6","key":"10276_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/cyto.a.23724","volume":"95","author":"CM Mousset","year":"2019","unstructured":"Mousset CM, Hobo W, Woestenenk R, Preijers F, Dolstra H, van der Waart AB (2019) Comprehensive phenotyping of T cells using flow cytometry. Cytometry A 95(6):647\u2013654. https:\/\/doi.org\/10.1002\/cyto.a.23724","journal-title":"Cytometry A"},{"issue":"7","key":"10276_CR39","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1158\/2159-8290.Cd-23-1266","volume":"14","author":"KD Moynihan","year":"2024","unstructured":"Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, Ni I, Chen W, Lee Y, Liao-Chan S, Chen J, Schumacher TNM, Schreiber RD, Yeung YA, Djuretic IM (2024) IL2 targeted to CD8\u2009+\u2009T cells promotes robust effector T-cell responses and potent antitumor immunity. Cancer Discov 14(7):1206\u20131225. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-1266","journal-title":"Cancer Discov"},{"issue":"1 Suppl","key":"10276_CR40","doi-asserted-by":"publisher","first-page":"e826","DOI":"10.1111\/j.1365-2567.2009.03089.x","volume":"128","author":"L Mu","year":"2009","unstructured":"Mu L, Sun B, Kong Q, Wang J, Wang G, Zhang S, Wang D, Liu Y, Liu Y, An H, Li H (2009) Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 128(1 Suppl):e826\u2013836. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03089.x","journal-title":"Immunology"},{"issue":"1","key":"10276_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, Gao Y, He J (2023) Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer 22(1):121. https:\/\/doi.org\/10.1186\/s12943-023-01826-7","journal-title":"Mol Cancer"},{"issue":"807","key":"10276_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adg0699","volume":"16","author":"BT Orcutt-Jahns","year":"2023","unstructured":"Orcutt-Jahns BT, Emmel PC, Snyder EM, Taylor SD, Meyer AS (2023) Multivalent, asymmetric IL-2-Fc fusions show enhanced selectivity for regulatory T cells. Sci Signal 16(807):eadg0699. https:\/\/doi.org\/10.1126\/scisignal.adg0699","journal-title":"Sci Signal"},{"issue":"9","key":"10276_CR43","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, Brighina F, Rini N, Puorro G, Marsili A, Garibaldi M, Fionda L, Sacc\u00e0 F (2024) A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol 271(9):6209\u20136219. https:\/\/doi.org\/10.1007\/s00415-024-12588-7","journal-title":"J Neurol"},{"issue":"9","key":"10276_CR44","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","volume":"57","author":"ME Raeber","year":"2024","unstructured":"Raeber ME, Caspar DP, Zurbuchen Y, Guo N, Schmid J, Michler J, Martin AC, Steiner UC, Moor AE, Koning F, Boyman O (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity 57(9):2232\u20132250.e2210. https:\/\/doi.org\/10.1016\/j.immuni.2024.07.016","journal-title":"Immunity"},{"issue":"5","key":"10276_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/07853890802068582","volume":"40","author":"KJ Rautajoki","year":"2008","unstructured":"Rautajoki KJ, Kylaniemi MK, Raghav SK, Rao K, Lahesmaa R (2008) An insight into molecular mechanisms of human T helper cell differentiation. Ann Med 40(5):322\u2013335. https:\/\/doi.org\/10.1080\/07853890802068582","journal-title":"Ann Med"},{"key":"10276_CR46","doi-asserted-by":"publisher","unstructured":"Rose A, von Spee-Mayer C, Kloke L, Wun K, K\u00fchl A, Enghard P, Burmester GR, Riemekasten G, Humrich JY (2019) IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4\u2009+\u2009T Cells in Murine Lupus Nephritis. Cells, 8(10). https:\/\/doi.org\/10.3390\/cells8101234","DOI":"10.3390\/cells8101234"},{"issue":"2","key":"10276_CR47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clim.2009.03.523","volume":"132","author":"S Shandley","year":"2009","unstructured":"Shandley S, Martinez S, Krolick K (2009) IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4. Clin Immunol 132(2):246\u2013256. https:\/\/doi.org\/10.1016\/j.clim.2009.03.523","journal-title":"Clin Immunol"},{"issue":"3","key":"10276_CR48","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, LaPorte KM, Malek TR (2024) Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity 57(3):414\u2013428. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.001","journal-title":"Immunity"},{"key":"10276_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1280029","volume":"15","author":"X Song","year":"2024","unstructured":"Song X, He Y, Huo Y, Jiang H, Yu Y, Sun Y, Liu Z, Zhang Z (2024) Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab. Front Immunol 15:1280029. https:\/\/doi.org\/10.3389\/fimmu.2024.1280029","journal-title":"Front Immunol"},{"key":"10276_CR50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1749-6632.2012.06844.x","volume":"1274","author":"MC Souroujon","year":"2012","unstructured":"Souroujon MC, Aricha R, Feferman T, Mizrachi K, Reuveni D, Fuchs S (2012) Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci 1274:120\u2013126. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06844.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10276_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40744-023-00620-7","volume":"11","author":"Q Su","year":"2024","unstructured":"Su Q, Wang X, Li Y, Zhang J, Bai C, Wang X, Yang L, Zhang J, Zhang SX (2024) Efficacy, safety and the lymphocyte subset changes of low-dose IL-2 in patients with autoimmune rheumatic diseases: a systematic review and meta-analysis. Rheumatol Ther 11(1):79\u201396. https:\/\/doi.org\/10.1007\/s40744-023-00620-7","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10276_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26030","volume":"10","author":"J Sun","year":"2024","unstructured":"Sun J, Xie Q, Sun M, Zhang W, Wang H, Liu N, Wang M (2024) Curcumin protects mice with myasthenia gravis by regulating the gut microbiota, short-chain fatty acids, and the Th17\/Treg balance. Heliyon 10(4):e26030. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26030","journal-title":"Heliyon"},{"issue":"2","key":"10276_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40259-023-00635-0","volume":"38","author":"LM Tomasovic","year":"2024","unstructured":"Tomasovic LM, Liu K, VanDyke D, Fabilane CS, Spangler JB (2024) Molecular engineering of interleukin-2 for enhanced therapeutic activity in autoimmune diseases. BioDrugs 38(2):227\u2013248. https:\/\/doi.org\/10.1007\/s40259-023-00635-0","journal-title":"BioDrugs"},{"issue":"3","key":"10276_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K (2021) Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol 203(3):366\u2013374. https:\/\/doi.org\/10.1111\/cei.13546","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10276_CR55","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G, Humrich JY (2016) Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis 75(7):1407\u20131415. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207776","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10276_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","volume":"22","author":"LSK Walker","year":"2022","unstructured":"Walker LSK (2022) The link between circulating follicular helper T cells and autoimmunity. Nat Rev Immunol 22(9):567\u2013575. https:\/\/doi.org\/10.1038\/s41577-022-00693-5","journal-title":"Nat Rev Immunol"},{"key":"10276_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947341","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang SX, Chang JS, Cheng T, Jiang XJ, Su QY, Zhang JQ, Luo J, Li XF (2022) Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial. Front Immunol 13:947341. https:\/\/doi.org\/10.3389\/fimmu.2022.947341","journal-title":"Front Immunol"},{"issue":"1","key":"10276_CR58","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","volume":"76","author":"Z Wang","year":"2012","unstructured":"Wang Z, Wang W, Chen Y, Wei D (2012) T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol 76(1):54\u201361. https:\/\/doi.org\/10.1111\/j.1365-3083.2012.02703.x","journal-title":"Scand J Immunol"},{"issue":"10","key":"10276_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102645","volume":"19","author":"R Wu","year":"2020","unstructured":"Wu R, Li N, Zhao X, Ding T, Xue H, Gao C, Li X, Wang C (2020) Low-dose interleukin-2: biology and therapeutic prospects in rheumatoid arthritis. Autoimmun Rev 19(10):102645. https:\/\/doi.org\/10.1016\/j.autrev.2020.102645","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10276_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.clim.2013.05.009","volume":"148","author":"X Xie","year":"2013","unstructured":"Xie X, Mu L, Yao X, Li N, Sun B, Li Y, Zhan X, Wang X, Kang X, Wang J, Liu Y, Zhang Y, Wang G, Wang D, Liu X, Kong Q, Li H (2013) ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh\/Tfr helper cell profiles. Clin Immunol 148(2):162\u2013176. https:\/\/doi.org\/10.1016\/j.clim.2013.05.009","journal-title":"Clin Immunol"},{"issue":"1","key":"10276_CR61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12815","volume":"153","author":"G Yang","year":"2018","unstructured":"Yang G, Yang X, Zhang J, Li G, Zheng D, Peng A, Hu J, Xu L, Yang B, Yang H, Zhou W, Tuzun E, Li J (2018) Transcriptional repressor Blimp1 regulates follicular regulatory T-cell homeostasis and function. Immunology 153(1):105\u2013117. https:\/\/doi.org\/10.1111\/imm.12815","journal-title":"Immunology"},{"key":"10276_CR62","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5210459","volume":"2017","author":"B Ye","year":"2017","unstructured":"Ye B, Stary CM, Gao Q, Wang Q, Zeng Z, Jian Z, Gu L, Xiong X (2017) Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies. J Immunol Res 2017:5210459. https:\/\/doi.org\/10.1155\/2017\/5210459","journal-title":"J Immunol Res"},{"issue":"1","key":"10276_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34162-3","volume":"13","author":"JY Zhang","year":"2022","unstructured":"Zhang JY, Hamey F, Trzupek D, Mickunas M, Lee M, Godfrey L, Yang JHM, Pekalski ML, Kennet J, Waldron-Lynch F, Evans ML, Tree TIM, Wicker LS, Todd JA, Ferreira RC (2022) Low-dose IL-2 reduces IL-21(+) T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes. Nat Commun 13(1):7324. https:\/\/doi.org\/10.1038\/s41467-022-34162-3","journal-title":"Nat Commun"},{"issue":"3","key":"10276_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08830185.2023.2274574","volume":"43","author":"R Zhang","year":"2024","unstructured":"Zhang R, Zhao Y, Chen X, Zhuang Z, Li X, Shen E (2024) Low-dose IL-2 therapy in autoimmune diseases: an update review. Int Rev Immunol 43(3):113\u2013137. https:\/\/doi.org\/10.1080\/08830185.2023.2274574","journal-title":"Int Rev Immunol"},{"key":"10276_CR65","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2058964","volume":"2021","author":"X Zhang","year":"2021","unstructured":"Zhang X, Ge R, Chen H, Ahiafor M, Liu B, Chen J, Fan X (2021) Follicular helper CD4(+) T cells, follicular regulatory CD4(+) T cells, and inducible costimulator and their roles in multiple sclerosis and experimental autoimmune encephalomyelitis. Mediators Inflamm 2021:2058964. https:\/\/doi.org\/10.1155\/2021\/2058964","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10276_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, Liu T, Jin Y, Chen J, Liu H, Zhang X, Li Y, Zhou Y, Yang Y, Li R, Yao H, Liu Y, Li C, Li Y, Ren Limin, Su Yin, Sun Xiaolin, He Jing, Li Z (2022) Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther 7(1):67. https:\/\/doi.org\/10.1038\/s41392-022-00887-2","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10276_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01350-6","volume":"8","author":"H Zhou","year":"2023","unstructured":"Zhou H, Zhao X, Zhang R, Miao M, Pei W, Li Z, Li Y, He J, Li Z, Sun X (2023) Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE. Signal Transduct Target Ther 8(1):141. https:\/\/doi.org\/10.1038\/s41392-023-01350-6","journal-title":"Signal Transduct Target Ther"},{"key":"10276_CR68","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28:445\u2013489. https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101212","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10276_CR69","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/intimm\/dxv079","volume":"28","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Zou L, Liu YC (2016) T follicular helper cells, T follicular regulatory cells and autoimmunity. Int Immunol 28(4):173\u2013179. https:\/\/doi.org\/10.1093\/intimm\/dxv079","journal-title":"Int Immunol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-025-10276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-025-10276-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-025-10276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:12:18Z","timestamp":1773886338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-025-10276-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10276"],"URL":"https:\/\/doi.org\/10.1007\/s11481-025-10276-5","relation":{},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An equal contribution has been added to this article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Information"}}],"article-number":"9"}}